<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
🌱 來自: [[Huppert&rsquo;s Notes]]
 Management of Complications Associated with Advanced CKDESRD #🚧 施工中 Management of Complications Associated with Advanced CKD/ESRD Blood pressure/volume • Pathophysiology of hypertension in CKD: Complex and multifactorial, attributed to reduced nephron mass, increased Na+ retention, extracellular volume expansion, activation of hormones (RAAS) and the sympathetic nervous system, and endothelial dysfunction"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Management of Complications Associated with Advanced CKDESRD"><title>Management of Complications Associated with Advanced CKDESRD</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.d87dc1bc1d56b6639942f91a14b0a71d.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.c6ae313685db7e5884b54a47e34caf12.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Management of Complications Associated with Advanced CKDESRD</h1><p class=meta>最後更新於
Jan 22, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Management%20of%20Complications%20Associated%20with%20Advanced%20CKDESRD.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><blockquote class=info-callout><p></p><p>🌱 來自: <a class="internal-link broken">Huppert&rsquo;s Notes</a></p></blockquote><a href=#management-of-complications-associated-with-advanced-ckdesrd--施工中><h1 id=management-of-complications-associated-with-advanced-ckdesrd--施工中><span class=hanchor arialabel=Anchor># </span>Management of Complications Associated with Advanced CKDESRD #🚧 施工中</h1></a><a href=#management-of-complications-associated-with-advanced-ckdesrd><h3 id=management-of-complications-associated-with-advanced-ckdesrd><span class=hanchor arialabel=Anchor># </span>Management of Complications Associated with Advanced CKD/ESRD</h3></a><a href=#blood-pressurevolume><h5 id=blood-pressurevolume><span class=hanchor arialabel=Anchor># </span>Blood pressure/volume</h5></a><p>•   Pathophysiology of hypertension in CKD: Complex and multifactorial, attributed to reduced nephron mass, increased Na+ retention, extracellular volume expansion, activation of hormones (RAAS) and the sympathetic nervous system, and endothelial dysfunction</p><p>•   Goal blood pressure: Generally &lt;130/80 mmHg. This may be more liberal when accounting for certain factors, such as the degree of kidney disease, dialysis tolerance, polypharmacy, adverse effects of medication, and history of transplant.</p><p>•   Treatment:</p><p>-   Sodium restriction is a key element of BP control. Fluid restriction becomes more important when GFR is severely reduced.</p><p>-   Patients should monitor PO intake and weight. Dry weight is estimated by exam and maintained through diuresis or ultrafiltration during dialysis.</p><p>-   Pharmacotherapy:</p><p><strong>•</strong>   Diuretics</p><p>-   If a patient is still urinating, diuretics can assist with volume management</p><p>-   Diuretics depend on reaching active concentrations in the tubule lumen; higher doses are required with worsening renal function as urea competitively binds to the Organic Anion Transporter 1 (OAT1) which transports the diuretics into the tubular lumen</p><p>-   Most diuretics cause net fluid loss by preventing tubular sodium reabsorption</p><p>-   Loop diuretics will often be necessary if eGFR &lt;30 mL/min/1.73 m2 (Efficacy in reduced eGFR: bumetanide > furosemide > metolazone > chlorthalidone > hydrochlorothiazide).</p><p><strong>•</strong>   ACE inhibitors/ARBs</p><p>-   First-line antihypertensive in CKD, especially with proteinuria and relatively preserved native kidney function</p><p>-   Can cause hyperkalemia</p><p>-   Increase in creatinine after starting agents is not necessarily indicative of kidney injury; generally should not be discontinued unless eGFR decreases by >30%</p><p>-   Combination ACE/ARB associated with increased renal decline and generally contraindicated (<strong>ONTARGET study <em>Lancet 2008</em></strong>)</p><p><strong>•</strong>   Calcium channel blocker (CCB)</p><p>-   Do not need dose modification for renal clearance</p><p>-   Relatively few adverse effects, can cause lower extremity edema</p><p>-   Preferred class in CKD after ACE/ARB and diuretics; can reduce proteinuria</p><p><strong>•</strong>   Beta-blockers</p><p>-   Typically used if secondary prevention of cardiac events is warranted</p><p>-   Agents with combination alpha/beta antagonism are preferred to avoid metabolic effects of beta blockers, e.g., carvedilol and labetalol</p><p>-   Nonrenal clearance is preferred, e.g., carvedilol</p><p><strong>•</strong>   Clonidine</p><p>-   No renal dose adjustment</p><p>-   Often used for hypertension on days between dialysis sessions</p><p>-   Associated with rebound hypertension when discontinued or doses missed</p><a href=#anemia><h5 id=anemia><span class=hanchor arialabel=Anchor># </span>Anemia</h5></a><p>•   Pathophysiology: Results from decreased erythropoietin (EPO) production, EPO resistance, and decreased RBC lifespan</p><p>•   Treatment:</p><p>-   Goal Hgb 10–11.5 g/dL</p><p>-   Check iron studies in CKD patients with anemia</p><p>-   Guidelines recommend for transferrin saturation >30%, ferritin >500 ng/mL, though practice patterns vary widely and less stringent targets may be used (e.g., transferrin saturation >20% and ferritin >100 ng/mL)</p><p><strong>•</strong>   Ferritin can be increased with inflammatory states too</p><p><strong>•</strong>   Rule out GI bleeding if you detect iron deficiency</p><p>-   Iron supplementation</p><p><strong>•</strong>   IV iron is preferred in patients on hemodialysis. PO supplementation causes constipation, adds to pill burden, and is minimally absorbed compared to IV formulations.</p><p><strong>•</strong>   Iron sucrose (Venofer) and ferric gluconate (Ferrlecit) are the most commonly used formulations</p><p><strong>•</strong>   IV iron can cause anaphylaxis when first given; provide a test dose and administer slowly for patients who are IV iron naive</p><p>-   Erythropoietin-stimulating agents (ESAs)</p><p><strong>•</strong>   Give if patient is iron replete but remains below Hgb goal</p><p><strong>•</strong>   Three formulations:</p><p>-   Epoetin alfa (Epogen). 3× per week during HD or weekly in non-HD CKD.</p><p>-   Darbepoetin alfa (Aranesp). Weekly during HD or monthly in non-HD CKD.</p><p>-   Methoxy polyethylene glycol-epoetin beta (Mircera). Every 2 weeks.</p><p>-   RBC Transfusion</p><p><strong>•</strong>   Uses:</p><p>-   Consider pRBC transfusion if ESAs are contraindicated or unsuccessful</p><p>-   Administer pRBCs if anemia is symptomatic or severe (Hgb &lt;7 g/dL)</p><a href=#bone-mineral-metabolism><h5 id=bone-mineral-metabolism><span class=hanchor arialabel=Anchor># </span>Bone mineral metabolism</h5></a><p>•   Pathophysiology: Mineral bone disorder is due to secondary hyperparathyroidism, which has two main contributing factors:</p><p>-   Decreased 1-alpha-hydroxylase (made by the kidney) → decreased activation of 25-hydroxy vitamin D to 1,25-dihydroxy vitamin D → decreased Ca2+ absorption → decreased serum Ca2+ level → increased PTH</p><p>-   Poor phosphate excretion → elevated phosphate → increased PTH and decreased 1,25-dihydroxy vitamin D</p><p>•   Manifestations of CKD mineral bone disorder:</p><p>-   Mineral and hormone abnormalities</p><p><strong>•</strong>   Increased phosphate</p><p><strong>•</strong>   Increased PTH</p><p><strong>•</strong>   Decreased 1,25-dihydroxy vitamin D</p><p>-   Structural bone abnormalities</p><p><strong>•</strong>   Renal osteodystrophy: Range of abnormal bone pathology, bone turnover, and mineralization; includes osteomalacia, adynamic bone disease, and osteitis fibrosa cystica</p><p><strong>•</strong>   Increased alkaline phosphatase: Reflects osteoblast activity and bone turnover</p><p><strong>•</strong>   Increased FGF23: Secreted by osteocytes and involved in phosphate regulation</p><p>-   Calcification of blood vessels and soft tissue</p><p>•   Management of CKD mineral bone disorder:</p><p>-   Phosphate</p><p><strong>•</strong>   Phosphate level should ideally be within the normal range, though levels &lt;5.5 mg/dL are often tolerated by providers</p><p><strong>•</strong>   Phosphate binders are used to lower phosphate by preventing absorption of dietary phosphate</p><p><strong>•</strong>   Calcium-based phosphate binders (data below from <strong>ST. PETER et al. <em>AJKD</em> 2018</strong>)</p><p>-   Calcium acetate (Phoslo) 667 mg/tablet; 34% of ESRD patients on this medication, cheap ($678/user-yr), strongest binder</p><p>-   Calcium carbonate (Tums), cheap</p><p><strong>•</strong>   Non-calcium-based phosphate binders</p><p>-   Sevelamer (Renvela) 800 mg/tablet; preferred by some due to absence of calcium, 54% of ESRD patients on this medication, expensive ($2000–$4000/user-yr).</p><p>-   Lanthanum carbonate (Carbrenol); 5% ESRD patients on this medication, expensive ($5000/user-yr).</p><p>-   Iron-based phosphate binders: Ferric citrate and sucroferric oxyhydroxide. May be preferred if iron supplementation is needed.</p><p>-   Calcium</p><p><strong>•</strong>   Keep corrected Ca2+ within normal range</p><p><strong>•</strong>   Dialysate can be adjusted to address low or high Ca2+ levels</p><p><strong>•</strong>   Consider measuring ionized calcium (iCa) in patients with significant hypoalbuminemia, acidemia, or hyperphosphatemia</p><p>-   Vitamin D</p><p><strong>•</strong>   All CKD patients should be screened and treated for vitamin D deficiency or insufficiency (check 25-hydroxy vitamin D level). 1,25-dihydroxy vitamin D is not routinely measured in practice.</p><p><strong>•</strong>   Treat with cholecalciferol or ergocalciferol unless hypercalcemia or significant hyperphosphatemia is present</p><p>-   PTH</p><p><strong>•</strong>   Guidelines recommend that PTH remain within 2–9× the upper limit of normal (~150–600 pg/mL) in HD patients</p><p><strong>•</strong>   Practice varies and treatment in non-HD patients is controversial</p><p><strong>•</strong>   Treatment: Active vitamin D analogs or calcimimetics are prescribed for severely elevated or rising PTH with replete 25-hydroxy vitamin D</p><p>-   Active vitamin D: Analogs of 1,25-dihydroxy vitamin D</p><p>•   Calcitriol (Rocaltrol). PO. Usually used for non-HD patients.</p><p>•   Paricalcitol (Zemplar). Administered IV. Usually given with HD.</p><p>•   Doxicalciferol (Hectorol). Administered IV. Usually given with HD.</p><p>-   Calcimimetics: Competitive binder of Ca2+ sensing receptor, which regulates PTH release. Usually used when active vitamin D analogues are inadequate or contraindicated due to hypercalcemia. More expensive than active vitamin D analogues. Side effects: Can cause hypocalcemia, nausea and vomiting.</p><p>•   Cinacalcet (Sensipar) – PO; in use since 2004</p><p>•   Etelcalcetide (Parsabiv) – IV; given with HD</p><p>-   Parathyroidectomy: Reserved for severe and refractory hyperparathyroidism in CKD</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/hypercalcemia/ data-ctx="Management of Complications Associated with Advanced CKDESRD" data-src=/hypercalcemia class=internal-link>hypercalcemia</a></li><li><a href=/nephrology-diseases-and-pathophysiology/ data-ctx="Management of Complications Associated with Advanced CKDESRD" data-src=/nephrology-diseases-and-pathophysiology class=internal-link>nephrology diseases and pathophysiology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>